Driada Medical Primos

Methenolone Enanthate 100 mg/mL (Driada Medical Primos) is an injectable anabolic-androgenic steroid containing methenolone enanthate, also known as Primobolan Depot, at a concentration of 100 mg per mL, supplied in a 10 mL vial (1,000 mg total) by Driada Medical, a Europe-based manufacturer often associated with underground performance-enhancing drug markets. It is a dihydrotestosterone (DHT)-derived steroid with mild anabolic and low androgenic properties, primarily used off-label by bodybuilders and athletes during cutting cycles for lean muscle preservation, fat loss, and enhanced definition with minimal water retention or estrogenic effects. Medically, it has been used for muscle wasting conditions, anemia, or osteoporosis, but its therapeutic use is rare today due to regulatory restrictions and availability—most use is non-therapeutic and illegal without a prescription in many countries, including India.

How It Works

Methenolone enanthate binds to androgen receptors, promoting protein synthesis, nitrogen retention, and collagen production, which supports lean muscle maintenance and recovery while aiding fat loss. The enanthate ester ensures a slow release over 10-14 days after intramuscular injection, with a half-life of about 7-10 days, delivering steady, high-quality gains (typically 5-10 lbs of lean muscle per cycle). It has an anabolic-to-androgenic ratio of approximately 88:44-57 (relative to testosterone’s 100:100), does not aromatize to estrogen, and exhibits minimal progestogenic activity, making it ideal for achieving a dry, defined physique without bloating.

Dosage and Administration

• Administered via deep intramuscular injection into large muscle groups (e.g., glutes or deltoids) using sterile technique; typically injected every 7-10 days due to the long half-life.
• Non-medical bodybuilding doses: Men 400-600 mg per week (4-6 mL total), often in 8-12 week cycles; women 50-100 mg per week to minimize virilization risks. Beginners may start at 300-400 mg/week, often stacked with low-dose testosterone (e.g., 200-300 mg/week) for enhanced effects.
• For the 10 mL vial: Rotate injection sites to prevent irritation; monitor bloodwork for testosterone levels, lipids, liver enzymes, and hematocrit every 4-6 weeks. Post-cycle therapy (PCT) with selective estrogen receptor modulators (SERMs) like clomiphene (50 mg/day for 4 weeks) or tamoxifen (20 mg/day for 4 weeks) starts 2 weeks after the last injection to restore natural testosterone production.
• Professional administration is advised; avoid doses above 800 mg/week to reduce side effect risks.

Side Effects

Common side effects include:

• Androgenic: Mild acne, oily skin, accelerated hair loss (in those predisposed), and increased body hair; women may experience voice deepening or menstrual irregularities at higher doses.
• Cardiovascular/Endocrine: Cholesterol imbalances (decreased HDL, increased LDL), mild blood pressure elevation, and suppression of natural testosterone production (causing low libido or fatigue post-cycle).
• Injection-related: Pain, redness, or swelling at the injection site.

Serious risks: Mild liver stress (injectable form is less hepatotoxic than oral), potential prostate enlargement, mood changes (e.g., irritability), and virilization in women (clitoral enlargement, potentially irreversible). Long-term abuse may increase risks of cardiovascular disease or infertility; no significant estrogenic effects like gynecomastia due to non-aromatization. Discontinue immediately if severe symptoms like jaundice, chest pain, or swelling occur and seek medical attention.

Precautions and Warnings

• Contraindicated in individuals with prostate or breast cancer, severe heart/liver/kidney disease, hypercalcemia, pregnancy, breastfeeding, or hypersensitivity to components (e.g., carrier oil, often grape seed in Driada products).
• Use caution in those with high cholesterol, hypertension, diabetes (may alter glucose control), or bleeding disorders; not suitable for minors (risk of premature epiphyseal closure) or women beyond low therapeutic doses due to virilization risks.